CN102344478B - 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 - Google Patents
一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 Download PDFInfo
- Publication number
- CN102344478B CN102344478B CN 201110207825 CN201110207825A CN102344478B CN 102344478 B CN102344478 B CN 102344478B CN 201110207825 CN201110207825 CN 201110207825 CN 201110207825 A CN201110207825 A CN 201110207825A CN 102344478 B CN102344478 B CN 102344478B
- Authority
- CN
- China
- Prior art keywords
- cdb
- crystal
- preparation
- crystallisate
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229960003328 benzoyl peroxide Drugs 0.000 title claims abstract description 6
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims abstract description 56
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 11
- 238000002425 crystallisation Methods 0.000 claims abstract description 10
- 230000008025 crystallization Effects 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000012296 anti-solvent Substances 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical group O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 claims 1
- 238000001228 spectrum Methods 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract 2
- 238000004807 desolvation Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 14
- 238000002411 thermogravimetry Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 238000013019 agitation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 229940096118 ella Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- HKDLNTKNLJPAIY-WKWWZUSTSA-N Ulipristal Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
2θ(°) | 相对强度(%) |
9.085 | 100.0 |
8.860 | 56.1 |
16.375 | 53.7 |
17.750 | 49.3 |
18.720 | 44.2 |
2θ(°) | 相对强度(%) |
9.110 | 100.0 |
16.965 | 64.1 |
15.130 | 41.3 |
15.010 | 41.2 |
17.165 | 39.2 |
2θ(°) | 相对强度(%) |
4.801 | 12.8 |
6.339 | 45.0 |
8.294 | 8.4 |
9.280 | 70.8 |
9.593 | 50.3 |
11.745 | 27.5 |
12.691 | 42.6 |
13.362 | 15.2 |
15.178 | 39.0 |
16.654 | 32.6 |
17.309 | 100.0 |
18.628 | 84.7 |
19.222 | 21.7 |
20.994 | 34.7 |
21.373 | 16.8 |
22.062 | 8.6 |
22.476 | 10.4 |
23.619 | 6.2 |
24.113 | 11.1 |
26.857 | 9.6 |
样品 | 表观溶解度(mg/ml) |
结晶物(晶型C) | 0.000250 |
结晶物(晶型A) | 0.000125 |
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110207825 CN102344478B (zh) | 2011-07-22 | 2011-07-22 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
PCT/CN2012/078909 WO2013013595A1 (zh) | 2011-07-22 | 2012-07-20 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110207825 CN102344478B (zh) | 2011-07-22 | 2011-07-22 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102344478A CN102344478A (zh) | 2012-02-08 |
CN102344478B true CN102344478B (zh) | 2013-08-07 |
Family
ID=45543582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110207825 Active CN102344478B (zh) | 2011-07-22 | 2011-07-22 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102344478B (zh) |
WO (1) | WO2013013595A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102344478B (zh) * | 2011-07-22 | 2013-08-07 | 上海希迈医药科技有限公司 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
CN103755765B (zh) * | 2012-04-17 | 2018-01-02 | 常州市第四制药厂有限公司 | 醋酸乌利司他的多晶型及其制备方法 |
CN102675395B (zh) * | 2012-04-17 | 2014-04-30 | 常州市第四制药厂有限公司 | 醋酸乌利司他的多晶型及其制备方法 |
US9643994B2 (en) * | 2012-09-28 | 2017-05-09 | Aska Pharmaceutical Co., Ltd. | Crystalline polymorphic form of ulipristal acetate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101466723A (zh) * | 2006-06-14 | 2009-06-24 | 吉瑞工厂 | 用于合成17α-乙酰氧基-11β-[4-(N,N-二甲基-氨基)-苯基]-19-去甲孕甾-4,9-二烯-3,20-二酮的工业生产方法和用于所述方法的新的中间体 |
CN102241722A (zh) * | 2010-05-12 | 2011-11-16 | 杭州容立医药科技有限公司 | 一种合成孕酮受体调节剂优力司特的纯化方法 |
CN102295674A (zh) * | 2011-07-14 | 2011-12-28 | 四川大学 | 获得高纯度17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的方法 |
CN102372760A (zh) * | 2010-08-12 | 2012-03-14 | 杭州容立医药科技有限公司 | 一种合成孕酮受体调节剂优力司特的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
US5929262A (en) * | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
ES2212912B1 (es) * | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
WO2004078709A2 (en) * | 2003-02-28 | 2004-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES |
CN102344478B (zh) * | 2011-07-22 | 2013-08-07 | 上海希迈医药科技有限公司 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
CN102675395B (zh) * | 2012-04-17 | 2014-04-30 | 常州市第四制药厂有限公司 | 醋酸乌利司他的多晶型及其制备方法 |
-
2011
- 2011-07-22 CN CN 201110207825 patent/CN102344478B/zh active Active
-
2012
- 2012-07-20 WO PCT/CN2012/078909 patent/WO2013013595A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101466723A (zh) * | 2006-06-14 | 2009-06-24 | 吉瑞工厂 | 用于合成17α-乙酰氧基-11β-[4-(N,N-二甲基-氨基)-苯基]-19-去甲孕甾-4,9-二烯-3,20-二酮的工业生产方法和用于所述方法的新的中间体 |
CN102241722A (zh) * | 2010-05-12 | 2011-11-16 | 杭州容立医药科技有限公司 | 一种合成孕酮受体调节剂优力司特的纯化方法 |
CN102372760A (zh) * | 2010-08-12 | 2012-03-14 | 杭州容立医药科技有限公司 | 一种合成孕酮受体调节剂优力司特的合成方法 |
CN102295674A (zh) * | 2011-07-14 | 2011-12-28 | 四川大学 | 获得高纯度17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102344478A (zh) | 2012-02-08 |
WO2013013595A1 (zh) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102344478B (zh) | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 | |
EP3241837A1 (en) | Method for preparing sofosbuvir crystal form-6 | |
JP2023103328A (ja) | ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス | |
CN102675395B (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
CN102321141B (zh) | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的无定形物及其制备方法 | |
CN102558275A (zh) | α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物 | |
CN106478636B (zh) | 替格瑞洛晶型及制备方法 | |
CN105175355B (zh) | 一种2-氰基吩噻嗪的制备方法 | |
CN114008023B (zh) | 索吡溴铵的晶型及其制备方法 | |
CN107056691B (zh) | 一种制备依托考昔晶型v的方法 | |
CN104496829A (zh) | 一种盐酸达泊西汀的新晶型及其制备方法与应用 | |
CN110964017A (zh) | 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途 | |
CN106336363A (zh) | 一种沙芬酰胺甲磺酸盐晶型c及其制备方法 | |
CN110759848A (zh) | 一种乙磺酸尼达尼布杂质及其制备方法和应用 | |
CN104151192A (zh) | 一种米屈肼中间体3-(2,2,2-三甲基肼)丙酸甲酯甲基硫酸盐制备技术的改进方法 | |
CN115785048B (zh) | 一种gl-v9晶型及其制备方法 | |
CN111362816B (zh) | 他莫昔芬有关物质的制备方法 | |
CN109293519B (zh) | 一种枸橼酸他莫昔芬晶型a的制备方法 | |
CN111320601B (zh) | 一种千层纸素晶型及其制备方法 | |
CN102417489B (zh) | 一种盐酸司他斯汀晶型f及其制备方法 | |
CN107759670A (zh) | 硫酸多粘菌素b1、b2或其混合物的结晶及其制备方法 | |
CN107417599A (zh) | 一种依托考昔晶型的制备方法 | |
CN116715660A (zh) | 一种特格拉赞的无定型物及其制备方法 | |
CN103755765B (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
CN113387792A (zh) | 一种洛索洛芬钠工艺杂质的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU XIDI PHARMACEUTICAL CO., LTD. SHANGHAI ACE Free format text: FORMER OWNER: JIANGSU XIDI PHARMACEUTICAL CO., LTD. Effective date: 20141219 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141219 Address after: 201203, 1999 Zhang Heng Road, Shanghai, 9, building 3, Pudong New Area Patentee after: SHANGHAI XIMAI MEDICAL TECHNOLOGY Co.,Ltd. Patentee after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: 201203, 1999 Zhang Heng Road, Shanghai, 9, building 3, Pudong New Area Patentee before: SHANGHAI XIMAI MEDICAL TECHNOLOGY Co.,Ltd. Patentee before: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191009 Address after: No. 1479 Zhangheng Road, China (Shanghai) Free Trade Pilot Area, 201203 Co-patentee after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Co-patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: 201203, 1999 Zhang Heng Road, Shanghai, 9, building 3, Pudong New Area Co-patentee before: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI XIMAI MEDICAL TECHNOLOGY Co.,Ltd. Co-patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 201203, 1999 Zhang Heng Road, Shanghai, 9, building 3, Pudong New Area Co-patentee after: JIANGSU ACEBRIGHT PHARMACEUTICALS Co.,Ltd. Patentee after: SHANGHAI XIMAI MEDICAL TECHNOLOGY Co.,Ltd. Co-patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: 201203, 1999 Zhang Heng Road, Shanghai, 9, building 3, Pudong New Area Co-patentee before: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI XIMAI MEDICAL TECHNOLOGY Co.,Ltd. Co-patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191112 Address after: No. 1479 Zhangheng Road, China (Shanghai) Free Trade Pilot Area, 201203 Co-patentee after: JIANGSU ACEBRIGHT PHARMACEUTICALS Co.,Ltd. Patentee after: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Co-patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: 201203, 1999 Zhang Heng Road, Shanghai, 9, building 3, Pudong New Area Co-patentee before: JIANGSU ACEBRIGHT PHARMACEUTICALS Co.,Ltd. Patentee before: SHANGHAI XIMAI MEDICAL TECHNOLOGY Co.,Ltd. Co-patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 1479 Zhangheng Road, China (Shanghai) Free Trade Pilot Area, 201203 Patentee after: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: No. 1479 Zhangheng Road, China (Shanghai) Free Trade Pilot Area, 201203 Patentee before: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU ACEBRIGHT PHARMACEUTICALS Co.,Ltd. Patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201224 Address after: 331208 salt chemical industrial base of Zhangshu City, Yichun City, Jiangxi Province Patentee after: Jiangxi desino Pharmaceutical Co.,Ltd. Patentee after: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. Address before: No. 1479 Zhangheng Road, China (Shanghai) Free Trade Pilot Area, 201203 Patentee before: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221101 Address after: 331299 Zhangshu salt chemical industrial base, Yichun City, Jiangxi Province Patentee after: Jiangxi desino Pharmaceutical Co.,Ltd. Patentee after: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Address before: 331208 salt chemical industrial base of Zhangshu City, Yichun City, Jiangxi Province Patentee before: Jiangxi desino Pharmaceutical Co.,Ltd. Patentee before: SHANGHAI DESANO BIO-PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd. |